ArticleJournal of managed care & specialty pharmacy2021
Real-world evidence for option value in metastatic melanoma.
Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- A systematic review of the applications of the real option value of medical technologies in oncology.Journal of managed care & specialty pharmacy · 2025Pooled it
- The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.Breast cancer research and treatment · 2026Article
- Val (EU) xit: do we need an international ISPOR value flower?Journal of comparative effectiveness research · 2024Article
- Incorporating Real Option Value in Valuing Innovation: A Way Forward.PharmacoEconomics · 2024Article
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.Forum for health economics & policy · 2024Article
- Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations.Future oncology (London, England) · 2024Article
- A review of HTA guidelines on societal and novel value elements.International journal of technology assessment in health care · 2023Review
- Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.PharmacoEconomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.